Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial

医学 传统PCI Evolocumab公司 血运重建 心脏病学 内科学 经皮冠状动脉介入治疗 支架 心肌梗塞 外科 载脂蛋白B 胆固醇 载脂蛋白A1
作者
Kazuma Oyama,Remo H M Furtado,Antônio Fagundes,Thomas A. Zelniker,Minao Tang,Julia Kuder,Sabina A. Murphy,Andrew Hamer,Huei Wang,Anthony Keech,Terje R. Pedersen,Robert P. Giugliano,Marc S. Sabatine,Brian Bergmark
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:142 (Suppl_3) 被引量:3
标识
DOI:10.1161/circ.142.suppl_3.14770
摘要

Introduction: Although PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall, their ability to specifically reduce the risk of complex coronary atherosclerosis requiring revascularization has not been explored. Methods: FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients with ASCVD on statin therapy (median achieved LDL-C 32 mg/dL vs. 89 mg/dL) followed for a median of 2.2 years. The study database was blindly reviewed to assess characteristics of coronary revascularization procedures. Complex revascularization was the composite of complex PCI (per GLOBAL LEADERS criteria, at least one of: multivessel PCI, 3 or more stents implanted, 3 or more lesions treated, bifurcation PCI with 2 or more stents, or total stent length >60 mm) or CABG. PCI complications included no-reflow, side branch loss, thrombus formation, major dissection, or perforation. The effects of evolocumab on types of revascularization and PCI complications were evaluated using Cox proportional hazards models. Results: 1724 patients underwent revascularization procedures during follow-up. Evolocumab reduced the risk of non-complex PCI by 22% (HR 0.78; 95%CI 0.70-0.88; P<0.001) and the risk of complex revascularization by 29% (HR 0.71; 95%CI 0.61-0.84; P<0.001), including complex PCI by 33% (HR 0.67; 95%CI 0.54-0.84; P<0.001) and CABG by 24% (HR 0.76; 95%CI 0.60-0.96; P=0.019; Figure). The incidence of reported PCI complications tended to be lower with evolocumab (HR 0.74; 95% CI 0.49-1.11). Conclusions: Adding evolocumab to statin therapy reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. Together with prior coronary imaging findings, these data suggest very aggressive LDL-C lowering to <1 mmol/L has beneficial effects on coronary atherosclerosis burden, anatomical complexity, and the need for intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刻苦的砖头完成签到 ,获得积分10
1秒前
2秒前
谨慎垣完成签到,获得积分10
2秒前
2秒前
初景发布了新的文献求助10
4秒前
4秒前
忧虑的碧彤完成签到,获得积分10
5秒前
火星上的芳芳完成签到,获得积分10
5秒前
路知行完成签到,获得积分10
6秒前
8秒前
9秒前
任性吐司完成签到 ,获得积分10
9秒前
忆之发布了新的文献求助10
10秒前
11秒前
七听应助仁爱的沛儿采纳,获得30
11秒前
11秒前
大力思萱发布了新的文献求助10
12秒前
李爱国应助unowhoiam采纳,获得10
13秒前
yiyiii发布了新的文献求助10
13秒前
碧蓝明雪应助杨耑耑采纳,获得10
13秒前
17秒前
wakgyl应助米娅采纳,获得10
17秒前
蜘蛛侠发布了新的文献求助10
17秒前
小咸鱼完成签到,获得积分10
17秒前
竹萧发布了新的文献求助20
19秒前
所所应助wangqiqi采纳,获得10
20秒前
20秒前
Peggie发布了新的文献求助30
20秒前
20秒前
keyan123完成签到,获得积分10
21秒前
YY发布了新的文献求助10
22秒前
25秒前
大个应助lyla采纳,获得10
25秒前
拳击帅哥完成签到,获得积分10
26秒前
nn发布了新的文献求助30
26秒前
研友_VZG7GZ应助易安采纳,获得10
30秒前
忆之完成签到,获得积分10
30秒前
30秒前
科目三应助nlby采纳,获得10
32秒前
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Autoparametric Resonance in Mechanical Systems 1000
Effects of Two Weeks of Red Light Therapy on Choroidal Thickness and Axial Length in Young Adults 700
Cosmos as Art Object: Studies in Plato's Timaeus and Other Dialogues 600
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Auslegungsgeschichte 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7663913
求助须知:如何正确求助?哪些是违规求助? 9233517
关于积分的说明 19864465
捐赠科研通 7232582
什么是DOI,文献DOI怎么找? 3282592
关于科研通互助平台的介绍 2441939
邀请新用户注册赠送积分活动 2283756